Investing.comDoubao · 实盘不做把握 7/10不做原因:标的无直接敞口
北京时间·🕒 发布 21:04:36·⟳ 抓取 21:05:36 +1m00s·⚡ 决策 10-08 21:07:29 +1m53s·19.0 天前
Myriad Genetics 与 SOPiA GENETICS 联合阿斯利康推进前列腺癌生物标志物 PrGIS，属早期研发合作
这是一项无财务条款、处于临床验证早期的研发合作，且系 Myriad 与 SOPHiA、SOPHiA 与阿斯利康既有合作的延伸，对三家公司均无可量化的近期收入或盈利影响，缺乏可交易的短期 edge。
📄 原文Investing.com↗ 原文
Myriad Genetics, SOPHiA partner on prostate cancer biomarker
By Investing.com Advertisement Advertisement Myriad Genetics, SOPHiA partner on prostate cancer biomarker Company News…
不做 Myriad Genetics（MYGN.US）
早期无金额研发合作、系既有合作延伸，前列腺癌适应症未获批，短期无收入增量，缺乏可交易 edge。
不做 SOPHiA GENETICS（SOPH.US）
去中心化伴随诊断尚在开发、无财务条款，对营收无可量化影响，软催化不构成正期望。
不做 AstraZeneca（AZN.US）
超大市值药企，单一早期诊断合作不具重大性。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
三方合作推进前列腺癌 HRD 生物标志物 PrGIS，但仅为早期研发与伴随诊断开发，未披露金额或商业化时点，且属既有合作扩展，对 MYGN/SOPH 短期业绩无可量化增量、对 AZN 微不足道，故不做。
🔎 新鲜度:最早出现 2026-10-08 · 扩散 low · price-in 风险 low ↗
消息传播链
- Investing.com 基于新闻稿报道三方 PrGIS 合作，未披露金额；发布时美股盘前，尚未见市场重定价。
关键理由
- PrGIS 仍处临床试验与验证阶段，MyChoice CDx 前列腺癌适应症尚未获批，不构成近期收入。
- Myriad 与 SOPHiA 及 SOPHiA 与阿斯利康在 2025 年 9 月已有合作，本次为渐进式扩展，预期差有限。
主要风险
- 若 ESMO 2026 数据强劲并伴随监管或合作进展，可能带来情绪性反弹，但那是后续独立催化。
- 小盘诊断股对合作新闻可能有短期情绪波动，但无基本面支撑、追高风险大。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-08 · 影响 weakens
公告及报道均未披露任何金额、里程碑付款或收入指引，无法量化近期业绩增量。
检索:PrGIS collaboration financial terms revenue milestone Myriad SOPHiA 原文 ↗
先例如何影响了这次决策
对本次决策的影响:未改变结论，早期无金额研发合作缺乏正期望。
方向:无可对照的高相似先例，且本条因无 materiality 已判定不做，无需以先例校准幅度。
涨幅量级:无可用对齐先例校准涨幅。
形态:未做先例统计，不影响 AVOID 结论。
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`mygn soph prgis homologous recombination deficiency companion diagnostic | myriad genetics sophia genetics prgis prostate cancer biomarker collaboration astrazeneca | myriad mychoi`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - web_search 成功 doubao_search · 1,857 ms
豆包搜索结果（原始查询:Myriad Genetics SOPHiA GENETICS PrGIS prostate cancer collaboration press release；API SearchType:web）
原文全文
展开原文 · 7,285 字
Myriad Genetics, SOPHiA partner on prostate cancer biomarker By Investing.com
Advertisement
Advertisement
Myriad Genetics, SOPHiA partner on prostate cancer biomarker
Company News
Published
Oct 08, 2026, 09:04 AM
Myriad Genetics, SOPHiA partner on prostate cancer biomarker
View all comments (0)
0
Myriad Genetics, SOPHiA partner on prostate cancer biomarker
View all comments (0)
0
© Reuters
In this article:
MYGN
0.00%
SOPH
-3.12%
SALT LAKE CITY and BOSTON -
Myriad Genetics
Inc. (
NASDAQ:MYGN
) and SOPHiA GENETICS (
NASDAQ:SOPH
) announced today a collaboration with AstraZeneca (NYSE:AZN) to advance prostate cancer-specific genomic instability score technology for precision oncology applications, according to a press release statement.
The collaboration focuses on PrGIS, a biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency in prostate cancer patients. The companies aim to advance PrGIS in clinical trials and develop potential companion diagnostic solutions.
Myriad developed PrGIS to support homologous recombination deficiency as a biomarker in prostate cancer. The company’s MyChoice CDx test, currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for prostate cancer as a new indication.
SOPHiA GENETICS is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution that will incorporate Myriad’s PrGIS technology. The company’s cloud-based platform operates across a network of more than 1,000 connected institutions in over 75 countries.
Myriad plans to present PrGIS research, co-authored with AstraZeneca, at the European Society for Medical Oncology Congress 2026. The research is expected to characterize the biomarker and support its validation. Full data will be available following the ESMO embargo period.
The collaboration aims to expand patient access to PrGIS in global markets through SOPHiA GENETICS’ international laboratory network.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Myriad Genetics, SOPHiA partner on prostate cancer biomarker
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
50,878.60
-300.6
-0.59%
US 500
7,773.50
-28.2
-0.36%
Dow Jones
51,179.87
-341.41
-0.66%
S&P 500
7,801.77
-17.16
-0.22%
Nasdaq
27,538.69
-61.19
-0.22%
S&P 500 VIX
15.60
+0.52
+3.45%
Dollar Index
102.163
+0.150
+0.15%
Crude Oil WTI Futures
92.22
+3.94
+4.46%
Brent Oil Futures
104.49
+4.29
+4.28%
Natural Gas Futures
3.274
+0.071
+2.22%
Gold Futures
4,145.45
+4.75
+0.11%
Silver Futures
59.20
-1.094
-1.81%
Copper Futures
6.6313
-0.0182
-0.27%
US Soybeans Futures
1,292.00
-5.00
-0.39%
U.S. 10Y
5.313
+0.035
+0.66%
U.S. 30Y
5.687
+0.026
+0.46%
U.S. 5Y
5.073
+0.052
+1.04%
U.S. 3M
4.151
+0.010
+0.24%
US 10Y T-Note Futures
104.16
-0.33
-0.31%
Euro Bund Futures
120.71
-0.11
-0.09%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.67
+3.04
+0.91%
NVDA
237.47
-1.77
-0.74%
GOOGL
350.50
+2.82
+0.81%
TSLA
377.81
-2.87
-0.75%
AMZN
259.92
+3.63
+1.42%
NFLX
69.70
+1.01
+1.47%
META
721.31
-17.57
-2.38%
Advertisement
Most Popular Articles
News
Analysis
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oil prices surge amid Mideast shipping attacks, U.S. Gulf coast disruptions
By Investing.co
...
Oct 08, 2026
Up +32% MTD: As the tech rally spills over into these AI-picked restaurant plays
By Investing.co
...
Oct 08, 2026
AI debt deal wave reports; Applied Digital reports - what’s moving markets
By Investing.co
...
Oct 08, 2026
Wall Street posts first red session of October a day after notching a record close
By Investing.co
...
Oct 08, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
Q4 2026 Commodites Forecast: Will Gold and Silver Find a Bottom?
By Jeremy Wagne
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
SPCX
167.60
-2.51%
77.47M
AMD
645.86
-0.55%
18.56M
AAPL
336.67
+0.91%
34.15M
TSLA
377.81
-0.75%
25.59M
Name
Last
Chg. %
Vol.
NRG
108.61
+4.84%
5.39M
MRNA
196.48
+4.81%
14.64M
MU
1,088.00
+4.06%
30.86M
CTVA
14.45
+3.88%
41.33M
VST
166.72
+3.88%
12.01M
SMCI
44.94
+3.41%
40.54M
NTAP
235.77
+3.20%
3.00M
Name
Last
Chg. %
Vol.
MSTR
153.37
-6.79%
21.67M
SKYD
8.89
-6.72%
43.30M
CAT
813.83
-5.75%
3.34M
MHK
119.18
-5.45%
1.70M
NBIS
237.15
-5.09%
18.05M
CRWD
265.44
-4.81%
8.81M
BLDR
53.55
-4.75%
2.36M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
SPCX
167.60
-2.51%
77.47M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
APLD
23.810
-6.04%
48.76M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
Myriad Genetics, SOPHiA partner on prostate cancer biomarker
Company News
Published
Oct 08, 2026, 09:04 AM
Myriad Genetics, SOPHiA partner on prostate cancer biomarker
View all comments (0)
0
Myriad Genetics, SOPHiA partner on prostate cancer biomarker
View all comments (0)
0
© Reuters
In this article:
MYGN
0.00%
SOPH
-3.12%
SALT LAKE CITY and BOSTON -
Myriad Genetics
Inc. (
NASDAQ:MYGN
) and SOPHiA GENETICS (
NASDAQ:SOPH
) announced today a collaboration with AstraZeneca (NYSE:AZN) to advance prostate cancer-specific genomic instability score technology for precision oncology applications, according to a press release statement.
The collaboration focuses on PrGIS, a biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency in prostate cancer patients. The companies aim to advance PrGIS in clinical trials and develop potential companion diagnostic solutions.
Myriad developed PrGIS to support homologous recombination deficiency as a biomarker in prostate cancer. The company’s MyChoice CDx test, currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for prostate cancer as a new indication.
SOPHiA GENETICS is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution that will incorporate Myriad’s PrGIS technology. The company’s cloud-based platform operates across a network of more than 1,000 connected institutions in over 75 countries.
Myriad plans to present PrGIS research, co-authored with AstraZeneca, at the European Society for Medical Oncology Congress 2026. The research is expected to characterize the biomarker and support its validation. Full data will be available following the ESMO embargo period.
The collaboration aims to expand patient access to PrGIS in global markets through SOPHiA GENETICS’ international laboratory network.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Myriad Genetics, SOPHiA partner on prostate cancer biomarker
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
50,878.60
-300.6
-0.59%
US 500
7,773.50
-28.2
-0.36%
Dow Jones
51,179.87
-341.41
-0.66%
S&P 500
7,801.77
-17.16
-0.22%
Nasdaq
27,538.69
-61.19
-0.22%
S&P 500 VIX
15.60
+0.52
+3.45%
Dollar Index
102.163
+0.150
+0.15%
Crude Oil WTI Futures
92.22
+3.94
+4.46%
Brent Oil Futures
104.49
+4.29
+4.28%
Natural Gas Futures
3.274
+0.071
+2.22%
Gold Futures
4,145.45
+4.75
+0.11%
Silver Futures
59.20
-1.094
-1.81%
Copper Futures
6.6313
-0.0182
-0.27%
US Soybeans Futures
1,292.00
-5.00
-0.39%
U.S. 10Y
5.313
+0.035
+0.66%
U.S. 30Y
5.687
+0.026
+0.46%
U.S. 5Y
5.073
+0.052
+1.04%
U.S. 3M
4.151
+0.010
+0.24%
US 10Y T-Note Futures
104.16
-0.33
-0.31%
Euro Bund Futures
120.71
-0.11
-0.09%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.67
+3.04
+0.91%
NVDA
237.47
-1.77
-0.74%
GOOGL
350.50
+2.82
+0.81%
TSLA
377.81
-2.87
-0.75%
AMZN
259.92
+3.63
+1.42%
NFLX
69.70
+1.01
+1.47%
META
721.31
-17.57
-2.38%
Advertisement
Most Popular Articles
News
Analysis
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oil prices surge amid Mideast shipping attacks, U.S. Gulf coast disruptions
By Investing.co
...
Oct 08, 2026
Up +32% MTD: As the tech rally spills over into these AI-picked restaurant plays
By Investing.co
...
Oct 08, 2026
AI debt deal wave reports; Applied Digital reports - what’s moving markets
By Investing.co
...
Oct 08, 2026
Wall Street posts first red session of October a day after notching a record close
By Investing.co
...
Oct 08, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
Q4 2026 Commodites Forecast: Will Gold and Silver Find a Bottom?
By Jeremy Wagne
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
SPCX
167.60
-2.51%
77.47M
AMD
645.86
-0.55%
18.56M
AAPL
336.67
+0.91%
34.15M
TSLA
377.81
-0.75%
25.59M
Name
Last
Chg. %
Vol.
NRG
108.61
+4.84%
5.39M
MRNA
196.48
+4.81%
14.64M
MU
1,088.00
+4.06%
30.86M
CTVA
14.45
+3.88%
41.33M
VST
166.72
+3.88%
12.01M
SMCI
44.94
+3.41%
40.54M
NTAP
235.77
+3.20%
3.00M
Name
Last
Chg. %
Vol.
MSTR
153.37
-6.79%
21.67M
SKYD
8.89
-6.72%
43.30M
CAT
813.83
-5.75%
3.34M
MHK
119.18
-5.45%
1.70M
NBIS
237.15
-5.09%
18.05M
CRWD
265.44
-4.81%
8.81M
BLDR
53.55
-4.75%
2.36M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
SPCX
167.60
-2.51%
77.47M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
APLD
23.810
-6.04%
48.76M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
1ebc3e1e87· 2026-10-08 21:07 · doubao / doubao-seed-evolving-latest-version · 策略包0c89ec5cee9e当前